MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:93M1 • DE000A289V03

22.7 EUR
-0.4 (-1.73%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

2

93M1 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. While 93M1 seems to be doing ok healthwise, there are quite some concerns on its profitability. 93M1 has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year 93M1 has reported negative net income.
  • 93M1 had a positive operating cash flow in the past year.
  • In multiple years 93M1 reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: 93M1 reported negative operating cash flow in multiple years.
93M1.DE Yearly Net Income VS EBIT VS OCF VS FCF93M1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • 93M1's Return On Assets of -52.66% is on the low side compared to the rest of the industry. 93M1 is outperformed by 85.45% of its industry peers.
  • Looking at the Return On Equity, with a value of -56.18%, 93M1 is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
ROA -52.66%
ROE -56.18%
ROIC N/A
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
93M1.DE Yearly ROA, ROE, ROIC93M1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

1.3 Margins

  • In the last couple of years the Profit Margin of 93M1 has grown nicely.
  • The Profit Margin and Operating Margin and Gross Margin are not available for 93M1 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
93M1.DE Yearly Profit, Operating, Gross Margins93M1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • 93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for 93M1 remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, 93M1 has about the same amount of shares outstanding.
  • The debt/assets ratio for 93M1 has been reduced compared to a year ago.
93M1.DE Yearly Shares Outstanding93M1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
93M1.DE Yearly Total Debt VS Total Assets93M1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 5.57 indicates that 93M1 is not in any danger for bankruptcy at the moment.
  • 93M1 has a better Altman-Z score (5.57) than 74.55% of its industry peers.
  • 93M1 has a debt to FCF ratio of 5.58. This is a neutral value as 93M1 would need 5.58 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 5.58, 93M1 perfoms like the industry average, outperforming 50.91% of the companies in the same industry.
  • 93M1 has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • 93M1 has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. 93M1 outperforms 89.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 5.58
Altman-Z 5.57
ROIC/WACCN/A
WACC7.31%
93M1.DE Yearly LT Debt VS Equity VS FCF93M1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.
  • 93M1's Current ratio of 0.40 is on the low side compared to the rest of the industry. 93M1 is outperformed by 92.73% of its industry peers.
  • 93M1 has a Quick Ratio of 0.40. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 93M1 has a worse Quick ratio (0.40) than 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4
93M1.DE Yearly Current Assets VS Current Liabilites93M1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • 93M1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -196.45%.
  • Measured over the past years, 93M1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.67% on average per year.
  • 93M1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 104.72%.
  • 93M1 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.95% yearly.
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
93M1.DE Yearly Revenue VS Estimates93M1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
93M1.DE Yearly EPS VS Estimates93M1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 93M1. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
93M1.DE Price Earnings VS Forward Price Earnings93M1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 93M1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 46.28
EV/EBITDA N/A
93M1.DE Per share data93M1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • 93M1 has a Yearly Dividend Yield of 4.98%, which is a nice return.
  • 93M1's Dividend Yield is rather good when compared to the industry average which is at 1.95. 93M1 pays more dividend than 89.09% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, 93M1 pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.98%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
93M1.DE Yearly Dividends per share93M1.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
93M1.DE Yearly Income VS Free CF VS Dividend93M1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

More info and screens

Find the best dividend stocksShow peers with best dividend

MPH HEALTH CARE AG KONV

FRA:93M1 (2/5/2026, 7:00:00 PM)

22.7

-0.4 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20
Earnings (Next)05-26
Inst Owners1.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap97.16M
Revenue(TTM)52.00K
Net Income(TTM)-115.23M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.98%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1868.38
P/FCF 46.28
P/OCF 46.19
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-26.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.49
FCFY2.16%
OCF(TTM)0.49
OCFY2.16%
SpS0.01
BVpS47.93
TBVpS47.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.66%
ROE -56.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 4036.73%
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 5.58
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z 5.57
F-Score4
WACC7.31%
ROIC/WACCN/A
Cap/Depr(3y)20.66%
Cap/Depr(5y)19.86%
Cap/Sales(3y)15.7%
Cap/Sales(5y)12.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.36%
FCF growth 3YN/A
FCF growth 5Y-24.11%
OCF growth 1Y40.11%
OCF growth 3YN/A
OCF growth 5Y-24.28%

MPH HEALTH CARE AG KONV / 93M1.DE FAQ

Can you provide the ChartMill fundamental rating for MPH HEALTH CARE AG KONV?

ChartMill assigns a fundamental rating of 2 / 10 to 93M1.DE.


What is the valuation status for 93M1 stock?

ChartMill assigns a valuation rating of 1 / 10 to MPH HEALTH CARE AG KONV (93M1.DE). This can be considered as Overvalued.


Can you provide the profitability details for MPH HEALTH CARE AG KONV?

MPH HEALTH CARE AG KONV (93M1.DE) has a profitability rating of 1 / 10.


How financially healthy is MPH HEALTH CARE AG KONV?

The financial health rating of MPH HEALTH CARE AG KONV (93M1.DE) is 4 / 10.


How sustainable is the dividend of MPH HEALTH CARE AG KONV (93M1.DE) stock?

The dividend rating of MPH HEALTH CARE AG KONV (93M1.DE) is 6 / 10 and the dividend payout ratio is 0%.